We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

338:HKEXSinopec Shanghai Petrochemical Co. Ltd. Class H Analysis

Data as of 2026-03-14 - not real-time

₩28,650.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Y‑Biologics is trading near its recent resistance level with the 20‑day SMA sitting above the 50‑day SMA, a bullish crossover that aligns with a positive MACD histogram and an RSI comfortably above 50, suggesting short‑term upward momentum.
However, the fundamentals are markedly weak: revenue has collapsed, operating and profit margins are deeply negative, debt-to-equity is extremely high, and the DCF‑derived fair value is less than half the current market price, indicating a substantial overvaluation. The combination of a decreasing volume trend, high 30‑day volatility, and a lack of dividend further underscores the precariousness of the rally.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Current price well above DCF fair value
  • Negative earnings and cash flow
  • Decreasing volume despite bullish technicals

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential upside if pipeline milestones are achieved
  • Persistently high debt and weak profitability
  • Volatile price action with mixed technical signals

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Biotech sector upside from successful drug approvals
  • Long‑term cash reserves could fund R&D
  • Current valuation may eventually correct if clinical data improves

Key Metrics & Analysis

Financial Health

Revenue Growth-72.50%
Profit Margin-241.85%
ROE-49.24%
ROA-14.21%
Debt/Equity139.03
Op. Cash Flow₩-5256522752
Free Cash Flow₩12.5B
Industry P/E26.2

Technical Analysis

TrendBullish
RSI61.1
Support₩20,050.00
Resistance₩28,750.00
MA 20₩24,982.50
MA 50₩24,584.00
MA 200₩17,661.05
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value₩12,885.87
GradeOvervalued
TypeValue

Risk Assessment

Beta0.48
Volatility101.37%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.